Advanced search
1 file | 403.62 KB

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

(2019) RHEUMATOLOGY. 58(2). p.197-205
Author
Organization
Abstract
The pathogenesis of SpA is multifactorial and involves a range of immune cell types and cytokines, many of which utilize Janus kinase (JAK) pathways for signaling. In this review, we summarize the animal and pre-clinical data that have demonstrated the effects of JAK blockade on the underlying molecular mechanisms of SpA and provide a rationale for JAK inhibition for the treatment of SpA. We also review the available clinical trial data evaluating JAK inhibitors tofacitinib, baricitinib, peficitinib, filgotinib and upadacitinib in PsA, AS and related inflammatory diseases, which have demonstrated the efficacy of these agents across a range of SpA-associated disease manifestations. The available clinical trial data, supported by pre-clinical animal model studies demonstrate that JAK inhibition is a promising therapeutic strategy for the treatment of SpA and may offer the potential for improvements in multiple articular and extra-articular disease manifestations of PsA and AS.
Keywords
ACTIVE RHEUMATOID-ARTHRITIS, INFLAMMATORY-BOWEL-DISEASE, SELECTIVE JAK1, INHIBITOR, PSORIATIC-ARTHRITIS, INADEQUATE RESPONSE, TOFACITINIB, CP-690, 550, MAINTENANCE THERAPY, PLAQUE PSORIASIS, PHASE IIB, MODERATE, spondyloarthropathies (including psoriatic arthritis), DMARDs, cytokines, and inflammatory mediators, bone, gastrointestinal, ligaments and, tendons, skin, synovium

Downloads

  • 3037 18Veale.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 403.62 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Veale, Douglas J., Dennis McGonagle, Iain B. McInnes, James G. Krueger, Christopher T. Ritchlin, Dirk Elewaut, Keith S. Kanik, et al. 2019. “The Rationale for Janus Kinase Inhibitors for the Treatment of Spondyloarthritis.” Rheumatology 58 (2): 197–205.
APA
Veale, D. J., McGonagle, D., McInnes, I. B., Krueger, J. G., Ritchlin, C. T., Elewaut, D., Kanik, K. S., et al. (2019). The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. RHEUMATOLOGY, 58(2), 197–205.
Vancouver
1.
Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. RHEUMATOLOGY. Oxford: Oxford Univ Press; 2019;58(2):197–205.
MLA
Veale, Douglas J. et al. “The Rationale for Janus Kinase Inhibitors for the Treatment of Spondyloarthritis.” RHEUMATOLOGY 58.2 (2019): 197–205. Print.
@article{8609253,
  abstract     = {The pathogenesis of SpA is multifactorial and involves a range of immune cell types and cytokines, many of which utilize Janus kinase (JAK) pathways for signaling. In this review, we summarize the animal and pre-clinical data that have demonstrated the effects of JAK blockade on the underlying molecular mechanisms of SpA and provide a rationale for JAK inhibition for the treatment of SpA. We also review the available clinical trial data evaluating JAK inhibitors tofacitinib, baricitinib, peficitinib, filgotinib and upadacitinib in PsA, AS and related inflammatory diseases, which have demonstrated the efficacy of these agents across a range of SpA-associated disease manifestations. The available clinical trial data, supported by pre-clinical animal model studies demonstrate that JAK inhibition is a promising therapeutic strategy for the treatment of SpA and may offer the potential for improvements in multiple articular and extra-articular disease manifestations of PsA and AS.},
  author       = {Veale, Douglas J. and McGonagle, Dennis and McInnes, Iain B. and Krueger, James G. and Ritchlin, Christopher T. and Elewaut, Dirk and Kanik, Keith S. and Hendrikx, Thijs and Berstein, Gabriel and Hodge, Jennifer and Telliez, Jean-Baptiste},
  issn         = {1462-0324},
  journal      = {RHEUMATOLOGY},
  language     = {eng},
  number       = {2},
  pages        = {197--205},
  publisher    = {Oxford Univ Press},
  title        = {The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis},
  url          = {http://dx.doi.org/10.1093/rheumatology/key070},
  volume       = {58},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: